Study identifier:D5130C00078
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
Coronary heart disease
Phase 3
No
90 mg Ticagrelor, 75mg Clopidogrel
All
0
Interventional
18 Years +
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Verified 01 May 2013 by AstraZeneca
AstraZeneca
-
Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Ticagrelor 90 mg Ticagrelor | Drug: 90 mg Ticagrelor Morning and Evening dose for 5 days |
Active Comparator: Clopidogrel 75mg Clopidogrel | Drug: 75mg Clopidogrel Morning dose for 5 days |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.